Retatrutide vs Danuglipron
Side-by-Side Comparison
| Attribute | Retatrutide | Danuglipron |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Oral GLP-1 Agonist (Small Molecule) |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon... | Danuglipron is a non-peptide, small-molecule agonist of the GLP-1 receptor. Unlike peptide GLP-1 agonists (semaglutide, liraglutide, tirzepatide), it is an orally bioavailable synthetic compound that... |
| Evidence Rating | B — Phase III / NDA Filed | B — Phase III / NDA Filed |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase III (once-daily modified-release formulation for T2D and obesity). Pfizer discontinued the twice-daily formulation development in 2023. |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | Common: nausea (up to 42%), vomiting, diarrhea — significantly higher rates than injectable GLP-1 agonists; High discontinuation rates in Phase II: up to 50% of patients in the highest dose group discontinued, primarily due to GI adverse events |
| Route | Subcutaneous (clinical trial formulation only) | Oral |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | 40–120 mg oral (Phase 2 tested up to 120 mg BID; MR formulation doses TBD) |
| Frequency | Once weekly | Once daily (modified-release) or twice daily (immediate-release) |
| Molecular Weight | N/A | N/A |
| Half-Life | ~6 days (allows once-weekly dosing) | ~6-8 hours (immediate-release formulation) |
Overview
Retatrutide and Danuglipron are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Danuglipron — Mechanism & Evidence
Danuglipron (PF-06882961) is a small-molecule, non-peptide oral GLP-1 receptor agonist developed by Pfizer. NOTE: Danuglipron is NOT a peptide — it is a synthetic small molecule included here for comparison with peptide-based GLP-1 agonists. It is in Phase III development for type 2 diabetes and obesity. Danuglipron was initially studied as a twice-daily formulation, but Pfizer shifted focus to a once-daily modified-release formulation after the twice-daily version showed high discontinuation rates due to GI side effects.
Key claims: Oral small-molecule GLP-1 agonism is feasible; Weight loss in Phase II; HbA1c reduction in T2D.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Danuglipron is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Danuglipron: Common: nausea (up to 42%), vomiting, diarrhea — significantly higher rates than injectable GLP-1 agonists High discontinuation rates in Phase II: up to 50% of patients in the highest dose group discontinued, primarily due to GI adverse events GI tolerability was the primary reason Pfizer discontinued the twice-daily formulation and pivoted to modified-release
Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Related Research News
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Retatrutide Monthly Research Cost in Australia Breakdown
Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.